TABLE 1.
MIC for T. vaginalis, E. histolytica, and G. duodenalis in drug susceptibility assays
| Isolate | MIC (μM)a | No. of attemptsb | Frequencyc (%) | Range (μM)d |
|---|---|---|---|---|
| T. vaginalis | ||||
| Anaerocult C (2 days) | ||||
| BRIS/92/STDL/F1623 | 3.2 | 9 | 66 | 1.6–6.3 |
| BRIS/92/STDL/F1623-M1 | >100 | 4 | 75 | 50–>100 |
| BRIS/98/BSHC/11147 | 6.3 | 4 | 75 | 3.2–6.3 |
| BRIS/92/STDL/B7268 | 25 | 4 | 25 | 25–>100 |
| Aerobic assay (2 days) | ||||
| BRIS/92/STDL/F1623 | 25 | 4 | 75 | 12.5–25 |
| BRIS/92/STDL/F1623-M1 | Dead | |||
| BRIS/92/BHSC/11147 | 50 | 4 | 75 | 50–100 |
| BRIS/92/STDL/B7268 | >200 | 4 | 100 | >200 |
| E. histolytica, Anaerocult A (1 day) | ||||
| HTH-56:MUTM | 12.5 | 4 | 50 | 12.5–50 |
| HTH-56:MUTM-M1 | 25 | 4 | 50 | 25–100 |
| HM1:IMSS | 25 | 3 | 100 | 25 |
| HM1:IMSS-M1 | 25 | 2 | 50 | 25–100 |
| G. duodenalis | ||||
| Anaerocult C (3 days) | ||||
| BRIS/83/HEPU/106 | 6.3 | 13 | 69 | 3.2–12.5 |
| BRIS/83/HEPU/106-2ID10 | 25 | 3 | 100 | 25 |
| WB-1B | 6.3 | 15 | 80 | 6.3–12.5 |
| WB-M3 | 50 | 3 | 100 | 50 |
| WB-M3-Alb | 6.3 | 3 | 100 | 6.3 |
| Albendazole assay | ||||
| BRIS/83/HEPU/106 | 3.2e | 9 | 44 | 0.8–3.2 |
| WB-1B | 3.2e | 11 | 63 | 1.6–3.2 |
| WB-M3-Alb | 12.5e | 3 | 66 | 6.3–12.5 |
a
Most frequently obtained MIC of metronidazole (Giardia only) or albendazole or lowest MIC (for BRIS/92/STDL/B7268 and HM1:IMSS-M1).
b
Number of 96-well plate assays. Each plate had at least three identical columns of test drug and at least one drug-free control column.
c
Percentage of attempts for which the mode was the MIC.
d
Range of MICs obtained.
e
Albendazole MICs; all other values are metronidazole MICs.